NEW YORK (GenomeWeb) – Cantor Fitzgerald yesterday initiated coverage of Thermo Fisher Scientific with a rating of Overweight and a price target of $194 per share.

In a note to investors, Cantor analyst Bryan Brokmeier said that as the largest company in the highly-fragmented life science tools and diagnostics sector, Thermo Fisher has "significant opportunity for organic growth at the expense of weaker competitors," adding that the company is "well-positioned to benefit from positive secular trends, as well as capture share given its position in attractive end markets."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.